---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-063653"
form_type: "8-K"
ticker: null
cik: "0001012477"
company_name: "AVADEL PHARMACEUTICALS PLC"
filed_at: "2024-05-21T23:59:59+00:00"
generated_at: "2026-06-01T10:15:53.426488+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Avadel Pharmaceuticals appoints Naseem Amin, M.D. to Board of Directors

## Summary
- Naseem Amin appointed effective May 17, 2024, as independent director.
- Granted option to purchase 49,500 shares at $15.94, vesting over three years.
- Amin is CEO of Orphalan SA with 30 years experience in biopharma and venture capital.
- Board cites Amin's expertise to support commercial launch of LUMRYZ for narcolepsy.

## SEC filing metadata
- accession: 0001104659-24-063653
- form_type: 8-K
- cik: 0001012477
- company_name: AVADEL PHARMACEUTICALS PLC
- filed_at: 2024-05-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1012477/000110465924063653/0001104659-24-063653-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1012477/000110465924063653/tm2414924d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-063653
- JSON: https://secwatch.observer/filing/0001104659-24-063653.json
- Plain text: https://secwatch.observer/filing/0001104659-24-063653.txt

## Key facts
- Executive change
  Naseem Amin, MD was appointed as Director at AVADEL PHARMACEUTICALS PLC.
  - Action: appointed
  - Role: Director
  source text: On May 17, 2024, the Board of Directors (the “Board”) of Avadel Pharmaceuticals plc (the “Company”) appointed Naseem Amin, MD to the Board, effective as of May 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1012477/000110465924063653/0001104659-24-063653-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.